LCMV gp33-41 TFA |
Katalog-Nr.GC39592
One-Click Copy Product Info
|
LCMV gp33-41 (TFA), das Carboxyl-erweiterte 11 AminosÄuren lange Peptid, ist eine lymphozytÄre Choriomeningitis-Virussequenz, die durch MHC-Klasse-I-H-2Db-MolekÜle eingeschrÄnkt und zytotoxischen T-Lymphozyten prÄsentiert wird.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LCMV gp33-41 TFA is a 9-amino acid cytotoxic T lymphocyte (CTL) epitope derived from the glycoprotein GP1 of the Lymphocytic Choriomeningitis Virus (LCMV). LCMV gp33-41 TFA mediates antiviral cellular immune responses by activating specific CD8⁺ cytotoxic T cells through H-2Db-restricted antigen presentation[1-2]. LCMV gp33-41 TFA can be utilized in research related to virus-specific T cell detection, investigation of immunological memory mechanisms, and the development of antiviral immunotherapy platforms[3-4].
In vitro, TCR-transgenic splenocytes were treated with LCMV gp33-41 TFA (5µM) for 2 hours, followed by stimulation with IL-2-containing medium for 5 days. LCMV gp33-41 TFA successfully induced and expanded activated GP33-specific CD8⁺ T effector cells[5]. Bone marrow-derived macrophages (BMDMs) were pulsed overnight with LCMV gp33-41 TFA (10ng/µL) and LPS (100ng/mL), and subsequently co-cultured with P14 CD8⁺ T cells specific for this antigen for 3 days. LCMV gp33-41 TFA induced the expression of the activation marker CD44 on T cells[6].
In vivo, bone marrow-derived dendritic cells (BMDCs) were pulsed with the LCMV gp33-41 TFA (1µM) for 1 hour. Subsequently, 100 to 1×10⁶ of these DCs were adoptively transferred into C57BL/6 mice via intravenous, subcutaneous, or direct intrasplenic injection. LCMV gp33-41 TFA efficiently induced a virus-specific cytotoxic T lymphocyte (CTL) response, conferring rapid and long-term protection against LCMV challenge to the mice. LCMV gp33-41 TFA also enabled the clearance of the virus from peripheral tissues (such as the ovaries and brain), thereby preventing lethal choriomeningitis[7]. The LCMV gp33-41 TFA (100µg) emulsified in complete Freund's adjuvant was used to subcutaneously prime C57BL/6 mice on day 0, followed by booster immunizations with the same dose of peptide emulsified in incomplete Freund's adjuvant on days 7 and 14. LCMV gp33-41 TFA induced only a low frequency of specific CD8 T cells in mice. The majority of these cells exhibited an effector-like phenotype (CD127⁻CD62L⁻) and expressed the inhibitory receptor PD-1[8].
References:
[1] Smyth M, Khamina K, Popa A, et al. Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus. Front Immunol. 2021 Jun 14;12:638485.
[2] Gairin JE, Mazarguil H, Hudrisier D, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.
[3] Fridkis-Hareli M, Reinherz EL. New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination. Med Immunol. 2004 Dec 8;3(1):2.
[4] Gallimore A, Glithero A, Godkin A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med. 1998 May 4;187(9):1383-93.
[5] Laidlaw BJ, Decman V, Ali MA, et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog. 2013 Mar;9(3):e1003207.
[6] Hering M, Madi A, Sandhoff R, et al. Sphinganine recruits TLR4 adaptors in macrophages and promotes inflammation in murine models of sepsis and melanoma. Nat Commun. 2024 Jul 18;15(1):6067.
[7] Ludewig B, Ehl S, Karrer U, et al. Dendritic cells efficiently induce protective antiviral immunity. J Virol. 1998 May;72(5):3812-8.
[8] Liu Y, Xu L, Jiang Y, et al. Phenotypic and functional analysis of LCMV gp33-41 TFA-specific CD8 T cells elicited by multiple peptide immunization in mice revealed the up-regulation of PD-1 expression on antigen-specific CD8 T cells. Cell Mol Immunol. 2007 Dec;4(6):431-7.
| Cell experiment [1]: | |
Cell lines | Splenocytes |
Preparation Method | Splenocytes were incubated with 5µM LCMV gp33-41 TFA peptide for two hours. After peptide removal, cells were cultured in IL-2-supplemented media for 5 days to generate effector CD8+ T cells. |
Reaction Conditions | 5µM; initial 2-hour pulse, followed by 5-day culture. |
Applications | LCMV gp33-41 TFA peptide stimulation induced the activation and expansion of antigen-specific CD8+ T cells, as measured by increased expression of activation markers (e.g., CD44) and acquisition of effector function. |
| Animal experiment [2]: | |
Animal models | Female C57BL/6 mice (6-8 weeks old) |
Preparation Method | Mice were immunized by subcutaneous injection of 100μg LCMV gp33-41 TFA emulsified in complete Freund's adjuvant (CFA) into the hind footpads on day 0. This was followed by booster immunizations with 100μg of the LCMV gp33-41 TFA in incomplete Freund's adjuvant (IFA) administered on days 7 and 14. |
Dosage form | 100μg; s.c.; prime on day 0 and boost on days 7 and 14. |
Applications | This prime-boost LCMV gp33-41 TFA elicited a low frequency of LCMV gp33-41 TFA-specific CD8 T cells in mice. The induced T cells predominantly exhibited an effector-like phenotype (CD127⁻CD62L⁻), expressed the inhibitory receptor PD-1 (particularly in the spleen and lymph nodes). |
References: | |
| Cas No. | SDF | ||
| Formula | C50H74N11F3015S | M.Wt | 1158.24 |
| Löslichkeit | DMSO : 100 mg/mL (86.34 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 863.4 μL | 4.3169 mL | 8.6338 mL |
| 5 mM | 172.7 μL | 863.4 μL | 1.7268 mL |
| 10 mM | 86.3 μL | 431.7 μL | 863.4 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)